United States

People: Emergent BioSolutions Inc (EBS)

EBS on New York Consolidated

27 Jun 2017
Change (% chg)

$-1.21 (-3.52%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

El-Hibri, Fuad 

Mr. Fuad El-Hibri is Executive Chairman of the Board of the Company. Mr. El-Hibri served as chief executive officer and as chairman of our board of directors. Mr. El-Hibri previously served as president from March 2006 to April 2007. Mr. El-Hibri served as chief executive officer and chairman of the board of directors of BioPort Corporation from May 1998 until June 2004, when, as a result of our corporate reorganization, BioPort became a wholly owned subsidiary of Emergent BioSolutions and was subsequently renamed as Emergent BioDefense Operations Lansing Inc. Mr. El-Hibri is chairman of East West Resources Corporation, a venture capital and business consulting firm, a position he has held since June 1990. He served as president of East West Resources from September 1990 to January 2004. In August 2016, Mr. El-Hibri became chairman of the board of directors of Aptevo Therapeutics, Inc., a publicly-traded biotech company which focuses on bringing novel oncology and hematology therapeutics to market. Mr. El- Hibri is a member of the board of directors of the U.S. Chamber of Commerce, a member of the advisory board of the Yale Healthcare Conference, a member of the board of directors of the International Biomedical Research Alliance, an academic joint venture among the National Institutes of Health, or NIH, Oxford University and Cambridge University. He also serves as chairman of the El-Hibri Foundation. Mr. El-Hibri has also served as a member of the board of trustees of American University from 2004 to 2010. Mr. El-Hibri received a master’s degree in public and private management from Yale University and a B.A. in economics from Stanford University. We believe Mr. El-Hibri’s qualifications to serve on our board of directors include his service on other boards as well as his prior business experience, including as our chief executive officer and a director.

Basic Compensation

Total Annual Compensation, USD 963,606
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,465,320
Fiscal Year Total, USD 2,428,930

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 84,594 2,259,140.00
Name Fiscal Year Total

Fuad El-Hibri


Daniel Abdun-Nabi


Robert Kramer


Adam Havey


Ronald Richard


Sue Bailey

As Of  30 Dec 2016